Ionizing radiation has become the most effective way to modify natural and synthetic
polymers through crosslinking, degradation, and graft polymerization. This review will …

Deferoxamine mesylate (DFO) is an FDA-approved, hexadentate iron chelator routinely
used to alleviate systemic iron burden in thalassemia major and sickle cell patients. Iron …

Ferroptosis is an iron-dependent form of oxidative cell death, and the inhibition of ferroptosis
is a promising strategy with which to prevent and treat neurological diseases. Herein we …

Iron chelators have been widely used to remove excess toxic iron from patients with
secondary iron overload. However, small molecule-based iron chelators can cause adverse …

Postmenopausal osteoporosis is one of the most prevalent skeletal disorders in women and
is featured by the imbalance between intraosseous vascularization and bone metabolism. In …

Patients with β-thalassemia are prone to complications such as cardiovascular diseases and
secretory gland injury due to iron overload (IO) and reactive oxygen species (ROS) …

Deferoxamine (DFO) is an FDA‐approved iron‐chelating agent which shows good
therapeutic efficacy, however, its short blood half‐life presents challenges such as the need …

Nanogels have come out as a great potential drug delivery platform due to its prominently
high colloidal stability, high drug loading, core-shell structure, good permeation property and …

Excess iron accumulation occurs in organs of patients with certain genetic disorders or after
repeated transfusions. No physiological mechanism is available to excrete excess iron and …

Macrophage immunotherapy represents an emerging therapeutic approach aimed at
modulating the immune response to alleviate disease symptoms. Nanomaterials (NMs) have …